Japan's MHLW has approved Novocure's Optune Lua device alongside PD-1/PD-L1 inhibitors to treat non-small cell lung cancer.

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult ...

Japan’s MHLW approves Novocure’s Optune Lua to treat unresectable advanced/recurrent non-small cell lung cancer: Baar, Switzerland Tuesday, September 16, 2025, 17:00 Hrs [IST] ...

An announcement from NovoCure ( ($NVCR) ) is now available. On September 15, 2025, Novocure announced that Japan’s Ministry ...

The La Quinta grad led the Blackhawks to a pair of CIF titles while setting some huge valley records along the way.

Residents of a Koreatown apartment building were told they would lose their parking spots to make way for accessory dwelling ...

A state law passed last year allows landlords to replace amenities, such as parking, with accessory dwelling units.

The researchers claimed to have discovered AI-supported ransomware for the first time. But this was a misunderstanding.

Cybercriminals are increasingly using generative AI tools to fuel their attacks, with new research finding instances of AI ...

PromptLock is only a prototype of LLM-orchestrated ransomware, but hackers already use AI in file encryption and extortion ...

Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.